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Studies have shown that the duodenum is a more common site (30--40%) 
of primary gastrinomas than previously reported. These tumors are often 
occult to conventional exploration, and their detection requires duodenot- 
omy and meticulous evaluation of the mucosa by eversion and direct 
palpation. Furthermore, tumors as smaU as 1 to 2 mm may be associated 
with iymph node metastases. Seven patients with duodenal gastrinomas 
treated during a 2-year period are reported. Four had sporadic ZoUinger- 
Ellison syndrome (ZES), and three had multiple endocrine neoplasia type 
I (MEN-I) syndrome. Ail seven patients had malignant duodenal gastri- 
nomas as proved by metastatic lymph nodes and in one case a large liver 
metastasis as well. Local excision of the tumor, iymph node excisions, and 
in one case liver Iobectomy resulted in eugastrinemia in the 4 with 
sporadic ZES. Two of the three with MEN-I were also eugastrinemic after 
similar procedures, with the addition of distal pancreatectomy. Duode- 
notomy is considered an essential procedure in sporadic ZES patients 
when no pancreatic tumor is found and in ail MEN-I/ZES patients, 
regardless of the pancreatic findings. Regional lymph node excisions are 
essential when a duodenal tumor has been found. 
At one time it was assumed that most patients with Zollinger- 
Ellison syndrome (ZES) had malignant pancreatic tumors with 
metastases that precluded a curative surgical resection. There- 
fore nearly ail patients were treated by total gastrectomy with 
the exception of a few with primary extrapancreatic tumors [1, 
2]. Once drugs became available that adequately controlled 
gastric acid hypersecretion,  more emphasis was placed on 
identifying ZES patients who were potentially curable by tumor 
resection. Currently, it is estimated that up to 40% of  patients 
with sporadic ZES have tumors that can be  successfully re- 
sected [3]. These patients have primary tumors arising in the 
pancreas or duodenum with or without regional lymph node 
spread but no liver metastases.  However,  during the past 
decade,  as many as 40% of patients proved biochemically to 
have ZES who have undergone exploration have had negative 
findings [4]. As a result, these patients were subsequently 
treated with drug therapy or had palliative surgical procedures 
such as selective vagotomy or even total gastrectomy. Further- 
more, in most centers, multiple endocrine neoplasia type I 
(MEN-I)/ZES patients have been treated by drugs without 
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exploration because of the assumption that, short of total 
pancreatectomy, their hypergastr inemia could not be controlled 
surgically [5]. Our experience during the last 10 years,  during 
which time transhepatic selective venous sampling for gastrin 
(TSVS) was used to regionalize the source of gastrin secretion, 
convinced us that small duodenal tumors (microadenomas) 
could easily be overlooked during a standard exploration and 
thus be the cause of a failed procedure [4, 6]. Recent studies 
have shown that the duodenum is a more common site of 
primary gastrinomas than previously thought [7-11]. It is cur- 
rently estimated that between 30% and 40% of patients with 
sporadic ZES have duodenal tumors and that nearly ail MEN-I  
patients with ZES have duodenal primary tumors with or 
without additional pancreatic neuroendocrine neoplasms [7]. In 
1989 we reported our experience with 5 patients with microgas- 
trinomas of the duodenum that were occult to conventional 
exploration for ZES [4]. In each case, a duodenotomy was 
required for their identification. Despite their small size (2 mm), 
these tumors were considered the sole source of hypergastrin- 
emia and were locally excised for cure. The tumors could not be 
palpated through the bowel wall and were found and visualized 
only after a duodenotomy and a meticulous evaluation o f  the 
mucosa by eversion and direct palpation. Preoperative TSVS 
for gastrin directed attention to the duodenum or head of the 
pancreas as a source of hypergastr inemia in each of these cases. 
Despite their small size, two of these tumors were associated 
with small metastatic lymph nodes. As a result of this experi- 
ence, duodenotomy and intraluminal exploration became essen- 
tial maneuvers to be used in a n y  operation for sporadic ZES 
patients when no tumor was found within the pancreas and 
routine components of any exploration in MEN-I /ZES patients, 
regardless of the pancreatic findings. Furthermore,  because 
primary duodenal gastrinomas as small as 2 mm had been 
proved to metastasize to local nodes, excision of ail peripan- 
creatic nodes in the region of a duodenal primary tumor was 
also considered essential. 
During the past  2 years,  an additional 7 patients with duode- 
nal gastrinomas were treated at the University of Michigan 
Medical Center (UMMC). The purpose of this paper  is to 
describe their management and thš results of surgical therapy. 
Four  of these patients had sporadic ZES, and three were 
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Fig. 1. Case 1: sporadic ZES in a 54-year-old woman. 
patients with MEN-I  syndrome in which ZES was a compo- 
nent. 
Patient Summaries:  Sporadic ZES 
Case 1 
A 54-year-old woman presented with a 6-year history of peptic 
ulcer disease consisting of  abdominal pain and upper gastroin- 
testinal (GI) bleeding. She also had a 2-year history of diarrhea 
and episodes of recurrent  pancreatitis thought to be alcohol- 
related. She was admitted to an outside hospital for pancreatitis 
and on investigation was found to have multiple gastric and 
duodenal ulcers. Her  serum gastrin level was 650 pg/ml and 
when stimulated with secretin rose to 1796 pg/ml. A CT scan 
showed a 3 cm calcified mass in the neck of the pancreas. After 
transfer to UMMC, a selective arterial secretin injection study 
(SASI) was performed, which regionalized a gastrin-producing 
tumor in the pancreatic-duodenal  region. 
At exploration, a 3 cm calcified mass was found in the neck of 
the pancreas (Fig. 1). The remaining pancreas felt perfectly 
normal on complete exploration. After the pancreatic head and 
duodenum were mobilized, a 1 cm posterior pancreatic lymph 
node was found and excised. It was positive for metastatic 
neuroendocrine tumor. Through an anterior duodenotomy, a 
0.15 cm neuroendocrine tumor was locally excised from the 
second part  of the duodenum. Other peripancreatic and peri- 
duodenal lymph nodes were removed,  but none was round to be 
positive for metastatic disease. A distal pancreatectomy was 
then performed for removal  of  the 3 cm lesion in the neck 
region. It was found to be a calcified cystic nodule with no  
neuroendocrine component.  Immunohistochemical  staining of 
the duodenal tumor and lymph node were positive for gastrin. 
The patient did well postoperat ively and was discharged 7 days 
later. Her  serum gastrin level 4 months later while on no 
medication was 80 pg/ml, and a secretin stimulation study 
showed no rise in gastrin levels. She remains asymptomatic and 
requires no medication 18 months after operation. 
Comments. This patient with sporadic ZES was found to have 
a microgastrinoma 1.5 mm in diameter that was undetectable 
until her duodenostomy was performed. Despite the small size 
of this neuroendocrine tumor, a single node on the posterior 
surface of the pancreas near the duodenum contained meta- 
static disease. Despite having only a local excision of primary 
tumor and lymph nodes, both basal and secretin-stimulated 
gastrin are normal; and for the present time she represents a 
biochemical " cu re . "  
Case 2 
A 53-year-old man had a long-standing history of peptic ulcer 
disease complicated by a perforated duodenal ulcer in 1974, 
which was treated by simple closure. Because of persistent 
ulcer symptoms, he underwent a partial gastrectomy and Bill- 
roth II procedure in 1982. His symptoms persisted; and in 1988, 
while on H2 antagonists, he presented with bleeding jejunal 
ulcers and a perforation. At  that time he underwent a more 
extensive gastric resection and vagotomy with a Roux-en-Y 
anastomosis.  In 1990 he presented to an outside hospital with 
severe esophagitis and a 1 cm bleeding marginal ulcer. While 
undergoing investigation he perforated his esophagus and re- 
quired open drainage of the right chest, revision of his gastro- 
jejunostomy, and insertion of a feeding jejunostomy tube. 
Serum gastrin levels were measured and found to be elevated. 
After his recovery,  he was transferred to the UMMC for further 
evaluation. His basal serum gastrin level was 760 pg/ml and rose 
to 1700 pg/ml after secretin stimulation. Angiograms revealed a 
tumor blush in the region of the  pancreatic head. Both TSVS for 
gastrin and SASI results were consistent with gastrin hyperse- 
cretion from the region of the pancreatic head or duodenum. At  
exploration, a 0.5 cm nodule was palpable in the duodenum just  
distal to his duodenal stump closure (Fig. 2). A duodenotomy 
was performed, and the lesion was excised with an ellipse of 
full-thickness duodenal wall. A 4 mm lymph node on the 
anterior surface of the pancreas next to the duodenum was 
excised that contained metastatic neuroendocrine tumor. Ail 
other peripancreatic lymph nodes were negative. Immunohis- 
tochemical staining of the duodenal tumor and adjacent meta- 
static lymph node were positive for gastrin. Postoperatively,  he 
did well and was discharged from the hospital 7 days later. 
Because of his previous esophageal perforation, he was contin- 
ued on omeprazole for 5 months after operation during which 
rime his serum gastrin levels were slightly elevated. Subsequent 
to discontinuing the omeprazole,  his serum gastrin levels have 
remained in the normal range, but he has not yet had a secretin 
stimulation test. 
Comments. This patient with a 17-year history of  complicated 
peptic ulcer disease was found to have a 0.5 cm primary 
gastrinoma in the duodenal wall, 1 cm distal to a closure of the 
duodenal stump 9 years before. The primary tumor, like others 
larger than 0.5 cm, was locally invasive in the muscularis and 
could not be locally excised from the submucosa. The involved 
lymph node in this case was normal in size and would not have 
been identified as metastatic without microscopic confirmation. 
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Case 3 
A 48-year-old woman presented to the UMMC with a 10-year 
history of peptic ulcer disease. Despite treatment with cimeti- 
dine, she had complained of  increasing abdominal pain and 
intermittent diarrhea for the past  2 years. On investigation, her 
basal serum gastrin level was 9900 pg/ml and rose to 15,000 
pg/ml after secretin stimulation. An angiogram revealed two 
areas of hypervasculari ty in t he  region of the pancreatic head. 
Both TSVS and SASI regionalized the source of the gastrin to 
the head of the pancreas or duodenum. At  exploration, no 
primary tumor was found in the head of the pancreas, but four 
enlarged metastatic lymph nodes were found along the upper 
edge of the pancreatic head as well a l  one behind the pylorus 
(Fig. 3). A duodenostomy was performed and a 0.5 • 0.3 cm 
submucosal lesion was found just  distal to the pylorus. This 
lesion was excised with a full-thickness ellipse of duodenal wall 
and proved to be a neuroendocrine tumor by microscopic 
study. Postoperatively,  the patient did well  and was discharged 
7 days later. Her serum gastrin level fell to 104 pg/ml while still 
on omeprazole.  Six months later, after discontinuing the drug, 
her serum gastrin levels were normal (95 pg/ml). 
Comments. This patient with a 10-year history of  ulcer disease 
and a 2-year history of diarrhea was evaluated for ZES because 
of intractable symptoms while on H2-blockers. Her  primary 
tumor of 0.5 cm was locally invasive in the muscularis and was 
associated with lymph node metastases that were much larger 
than the primary tumor. Excisi0n of the primary tumor after it 
was identified through the duodenostomy and regional lymph 
node dissection has normalized her serum gastrin level. She is 
asymptomatic and on no d rugs .  
Case 4 
A 38-year-old male physician had a 2-week history of  right 
upper quadrant pain and tenderness. Ultrasonography was 
performed and revealed a normal gallbladder but a 12 cm mass 
in the right lobe of the liver. A CT scan confirmed it, and a 
percutaneous needle biopsy was performed at an outside hos- 
pital. It identified a neuroendocrine tumor that stained positive 
for gastrin. A serum gastrin level was obtained and was 3800 
pg/ml. He was placed on sandistatin and omeprazole,  and was 
seen in consultation at several medical centers; recommenda- 
tions ranged from liver transplantation te a Whipple procedure 
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and right hepatic lobectomy. After being evaluated at the 
UMMC he underwent a TSVS and SASI in an attempt to 
localize the primary tumor. These studies, however,  suggested 
that the liver tumor might be the only source of gastrin, but they 
were diflicult to interpret because the basal gastrin level was so 
elevated (18,000 pg/ml). The patient elected to undergo an 
operation at the UMMC, and at exploration a single large 
metastasis (15 cm) was confined to the right lobe of the liver 
(Fig. 4). A right hepatic lobectomy was performed. Lymph 
nodes were excised from the hepatoduodenal  ligament along the 
common bile duct and were found positive for neuroendocrine 
tumor. Palpation of  the pancreas failed to reveal a tumor, and 
palpation of  the first three parts of the duodenum were also 
negative. However ,  several firm lymph nodes were found in the 
mesentery of the fourth portion of the duodenum, and a nodule 
was palpable in the duodenal wall at its junction with the 
proximal jejunum. Duodenotomy was performed in the fourth 
portion of the duodenum, and a 0.7 cm submucosal nodule was 
excised with a full-thickness ellipse of duodenal wall. The local 
mesenteric lymph nodes were excised, as were ail nodes along 
the superior mesenteric vein to the region of the neck of the 
pancreas as well as above the pancreas from celiac axis to the 
hepatic hilum. The final histopathologic report  revealed that the 
primary duodenal gastrinoma, nine metastatic lymph nodes, 
and the hepatic metastasis ail stained positive for gastrin. 
Postoperatively,  he did well and was discharged from the 
hospital 14 days later. His serum gastrin levels were normal 
during the early postoperat ive period (42-60 pg/ml), and ail 
medications were discontinued. Five months after his surgery, 
his gastrin level was 87 pg/ml and a follow-up CT scan showed 
a hypertrophied left lobe of the liver (regeneration) with no 
evidence of metastatic disease; a secretin stimulation test was 
normal. 
Comments.  This patient with a duodenal gastrinoma is the only 
one we have seen with a liver metastasis.  Although large, it was 
a solitary metastasis,  and a right lobectomy completely re- 
moved the lesion. The primary tumor was in the fourth portion 
of the duodenum, and regional dissection of involved lymph 
nodes required excision of a portion of the mesentery,  nodes 
along the superior mesenteric vein, and those above the neck of 
the pancreas to the hilum of the liver. Despite the extent of  his 
disease, all gross tumor could be removed,  resulting in eugas- 
trinemia and an asymptomatic patient with an intact stomach. 
On the basis of normal basal and secretin-stimulated gastrin 
levels, he is currently considered a biochemical as well as 
clinical " cu re "  8 months after operation. 
MEN-I/ZES 
Case 5 
A 35-year-old woman was first seen at the UMMC complaining 
of a 2-year history of abdominal pain and diarrhea that required 
hospitalization on several occasions for dehydration. Thirteen 
years previously she had undergone a parathyroidectomy for 
what was described as a parathyroid "adenoma . "  She had been 
placed on cimetidine without relief, but omeprazole did control 
her symptoms. Evaluation consisted of a basal serum gastrin 
level of 3790 pg/ml rising to 9000 pg/ml after secretin stimula- 
tion. A CT scan showed a 3.5 cm lesion in the body of  the 
pancreas and a 2.5 cm lesion in the region of  the uncinate 
process. An angiogram showed corresponding lesions in these 
locations that were vascular. TSVS and SASI studies regional- 
ized a gastrin-producing tumor to the head of the pancreas or 
duodenum. At  exploration, the two pancreatic tumors previ- 
ously identified were readily palpated (Fig. 5). A distal pancre- 
atectomy, preserving the spleen, was performed, and the 2.5 cm 
tumor in the uncinate process was easily enucleated. Several 
enlarged lymph nodes along the common bile duct and in the 
peripancreatic region were excised and found to contain meta- 
static neuroendocrine tumor. A duodenotomy was then per- 
formed, and two duodenal submucosal neuroendocrine tumors 
were found in the second part of the duodenum. These lesions 
were excised with a full-thickness ellipse of duodenal wall and 
were found to be 1 x 1 cm and 0.5 x 0.7 cm. Immunohisto- 
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chemical studies show that the uncinate tumor and both duo- 
denal tumors were positive for gastrin, as were ail lymph nodes 
containing metastases.  The neuroendocrine tumor in the tail of 
the pancreas was negative for gastrin. The large tumor in the 
body was an ectopic spleen. Her postoperative course was 
complicated by a small pancreatic fistula and a wound infection. 
She was continued on omeprazole 20 mg/day, and her serum 
gastrin levels have ranged from 140 to 240 pg/ml while on that 
drug. She remains asymptomatic 1 year  after her operation. 
Comments. Additional family history revealed that several 
members had peptic ulcer disease and have proved to have ZES 
as a component of MEN-I.  In this case, as is typical of many 
MEN-I  patients, the tumor in the tail of the pancreas did not 
secrete gastrin. However ,  this patient did have gastrin-secreting 
tumors in both the duodenum and the uncinate process of the 
pancreas. Because the patient has been reluctant to discontinue 
omeprazole,  it is difficult to determine if she has residual tumor 
because patients on this drug frequently have gastrin levels in 
the range of 100 to 250 pg/ml. This patient emphasizes that, 
regardless of the pancreatic findings in MEN-I  patients, the 
duodenum must also be explored because of the high likelihood 
of additional small tumors in the duodenal wall. 
Case 6 
A 45-year-old man was originally diagnosed as having peptic 
ulcer disease and hypergastrinemia in 1981 while being evalu- 
ated for dysphagia. He was found to have esophagitis with a 
stricture and was placed on cimetidine to control the hyper- 
acidity. During the last 2 years,  he had developed diarrhea and 
increasing abdominal pain. He had been placed on omeprazole,  
which controlled the symptoms. He was then transferred to the 
UMMC for further evaluation. Studies confirmed that he had 
hypergastrinemia with levels of 2000 to 3000 pg/ml. An angio- 
gram showed a tumor blush in the mid-body of the pancreas, 
and TSVS and SASI regionalized the source of gastrin to the 
area of  the pancreatic head or duodenum. Additional studies 
revealed hypercalcemia (calcium 10.7 mg/dl), an elevated intact 
serum parathyroid hormone (PTH) level, and hyperprolactin- 
emia. A diagnosis of the MEN-I  syndrome was made and the 
patient started on bromocriptine to shrink a pituitary tumor that 
was readily identified on CT scan. One month later, a neck 
exploration was performed for the hyperparathyroidism, and a 
subtotal parathyroidectomy wa:  performed in addition to a 
thymectomy to eliminate possible supernumerary glands. Un- 
der the same anesthesia, an exploratory celiotomy was carried 
out, and the pancreatic tumor seen on the angiogram was 
readily identified in the body of  the pancreas (Fig. 6). After  
further mobilization of  the pancreas,  a 5 cm lymph node 
posterior to the head of the pancreas was identified and excised; 
it was shown to contain metastatic neuroendocrine tumor. After  
performing a distal pancreatectomy,  duodenotomy was per- 
formed and three submucosal  neuroendocrine tumors were 
palpable in the first, third, and fourth portions of the duodenum. 
The small lesions in the more proximal duodenum were locally 
excised, but the one in the fourth portion was large enough that 
a wedge excision of a portion of  the duodenal wall was 
necessary through a second duodenostomy. Immunohisto- 
chemical studies showed that the duodenal  tumors were posi- 
tive for gastrin, as was the metastatic lymph node, but the 
tumor in the body of the pancreas contained no gastrin. 
Although his serum gastrin level fell to 67 pg/ml 4 weeks after 
his operation, it rose to 600 pg/ml with secretin stimulation. 
Three months after operation, his serum gastrin was 197 pg/ml 
while on omeprazole 20 mg/day. One year  after his operation he 
is asymptomatic but continues to take omeprazole 20 mg once 
a day; his most recent basal  serum gastrin level while on this 
drug was 355 pg/ml. 
Comments. It is difficult to determine why this patient,  who was 
diagnosed with ZES 10 years before being evaluated at the 
UMMC had not been evaluated further for MEN-I  syndrome or 
surgically explored. Because of the untreated hyperparathy-  
roidism, it was elected to treat  this abnormality first and, if ail 
went well, then proceed with abdominal exploration. Again, it 
should be noted that the predominant  tumor in the body of  the 
pancreas was negative on immunohistochemical  study for gas- 
trin. The fact that this patient had three primary neuroendocrine 
tumors in the duodenum is not unusual in MEN-I  patients. The 
patient has not been cured biochemically as determined by 
secretin stimulation studies, but basal serum gastrin levels,  
when he is not on omeprazole,  have been in the normal range. 
Whether he has another microadenoma in the duodenum or an 
overlooked metastatic lymph node cannot be determined at this 
time. 
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Fig. 6. Case 6: MEN-I in a 45-year-old 
man. 
Case 7 
A 46-year-old man with a 10-year history o f"hyperac t ive  bowel 
syndrome"  primarily manifested by diarrhea, presented to an 
outside hospital with a perforated duodenal ulcer and under- 
went celiotomy and Graham patch. Five days later, he reper- 
forated; and at exploration he was found to have a 3 cm ulcer in 
the second portion of the duodenum that was treated by 
primary closure and a proximal defunctioning gastrostomy 
tube. Seven days later, while recovering in the intensive care 
unit, he developed acalculous cholecystitis,  and at a third 
operation a gangrenous gallbladder was excised. He developed 
multiple organ system failure and was maintained on total 
parenteral  nutrition and life support for 5 weeks. After his 
subsequent recovery,  he was transferred to another hospital 
where ZES was diagnosed after basal serum gastrin levels of 
3000 pg/ml were obtained. A secretin stimulation study demon- 
strated a rise to 7000 pg/ml. He was also round to have 
esophagitis and an esophageal stricture that required treatment 
with repeated dilatations. He was treated with omeprazole 20 
mg qid and sandostatin,  which controlled the diarrhea and 
abdominal pain. He was then transferred to the UMMC, where 
laboratory studies confirmed the diagnosis of  ZES. He was also 
found to have an elevated serum calcium level of 11.6 mg/dl and 
an elevated serum PTH level. A diagnosis of MEN-I  syndrome 
was established. He underwent SASI,  which regionalized gas- 
trin secretion to the head of the pancreas.  
With these findings, he underwent a neck exploration and 
subtotal (3.5 glands excised) gland parathyroidectomy as well 
as thymectomy. Under  the same general anesthetic, abdominal 
exploration was performed, and a large subserosal perigastric 
abscess was found near the site of his gastrostomy tube (Fig. 7). 
A 3 cm neuroendocrine tumor was found in the body of the 
pancreas,  and a distal pancreatectomy and splenectomy were 
performed. On further exploration of the region of the head of 
the pancreas,  a 1 cm peripancreatic lymph node was found on 
the posterior surface of  the head of  the pancreas next to the 
duodenum. It was positive on frozen section for metastatic 
neuroendocrine tumor. A duodenotomy was performed, and a 
0.15 cm submucosal neuroendocrine tumor was removed from 
the second part of the duodenum. Both the duodenal and 
peripancreatic lymph node neuroendocrine tumors stained pos- 
itive for gastrin; however,  the tumor in the body of the pancreas 
stained only for somatostatin and glucagon. Postoperatively,  
the patient 's  course was complicated by gastric outlet obstruc- 
tion secondary to reaccumulation of the perigastric abscess that 
was successfully treated by percutaneous drainage and antibi- 
otic therapy. Because of the esophageal stricture, he was 
continued on omeprazole 20 mg at bedtime and periodic dilata- 
tions. His most recent serum gastrin level while on omeprazole 
was 185 pg/ml. The gastrostomy tube was removed 4 months 
postoperatively after it was determined the patient could eat 
solids without dysphagia. He has subsequently gained 25 
pounds, has returned to work, and is currently being evaluated 
for possible discontinuance of the omeprazole therapy. 
Comments. This patient, who had a 10-year history of diarrhea 
without evaluation of serum gastrin, developed life-threatening 
complications from ZES syndrome; and although the diagnosis 
of ZES was subsequently established, the diagnosis of the 
MEN-I syndrome was not made until 6 months later when he 
was referred to the UMMC. Because of untreated hyperpara- 
thyroidism, it was elected to perform parathyroidectomy fol- 
lowed by abdominal exploration. Once again, the largest tumor 
in this pat ient 's  MEN-I  pancreas was negative for gastrin, and 
the source of his ZES was a microgastrinoma with a metastatic 
peripancreatic lymph node. 
Discuss ion 
It has been appreciated only during the past  few years that 
many of the duodenal gastrinomas were too small and submu- 
cosally located to be detected by preoperative endoscopy,  
palpation, or intraoperative ultrasonography [4]. Additionally, 
even tumors as small as I to 2 mm have proved to be associated 
with regional lymph node metastases.  The fact that some 
patients were cured of hypergastrinemia years after a gastrec- 
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Fig. 7. Case 7: MEN-I in a 46-year-old man. 
tomy, when they were explored and a single lymph node 
containing gastrinoma was excised, led some to the concept of 
"pr imary lymph node gastr inoma" [9, 12]. The current evi- 
dence suggests that it is much more likely that these patients 
had overlooked primary duodenal microgastrinomas that were 
excised with their gastrectomy specimens, which did not in- 
clude the involved node(s). 
From our experience, it is now clear that if the patient with 
sporadic ZES has no evidence of a pancreatic tumor after a 
complete exploration, the entire duodenum, from pylorus to the 
ligament of Treitz, must be carefully evaluated. In addition, any 
peripancreatic or periduodenal lymph node(s) that are abnormal 
in size or consistency should be excised and sent for frozen 
section study. A metastatic lymph node may be helpful in 
determining the most appropriate location for a duodenotomy 
when no tumor is palpable. If, after these maneuvers,  no tumor 
has been found in the pancreas,  lymph nodes, or duodenum, we 
now consider duodenotomy an essential part  of a complete 
exploration for the ZES. 
We perform an anterior longitudinal duodenotomy approxi- 
mately 6 cm in length in the second part of the duodenum, after 
which an intraluminal digital examination from the antrum to 
the fourth portion of the duodenum is done. If  no submucosal 
tumor is palpable, the mucosa is everted and palpated meticu- 
lously in a circumferential fashion in order to detect tumors as 
small as 1 to 2 mm underneath the mucosa. Tumors smaller than 
4 mm in diameter are usually locally excised with a partial 
thickness of mucosa, tumor, and submucosa; and the site is 
closed from within with a few interrupted stitches. Most tumors 
that are 0.5 cm or larger are locally invasive in the submucosa 
and should be removed by excision of  a full-thickness ellipse of 
duodenal wall with a margin around the tumor [8]. Because the 
larger lesions can usually be palpated, a duodenotomy can be 
planned so the excisional site can be included in the duodenot- 
omy closure rather than having to close a second duodenotomy. 
In most cases, the duodenotomy has been closed with a 
full-thickness running absorbable suture and a second layer of 
interrupted silk sutures. Once this step has been completed, any 
remaining lymph nodes, regardless of size, in the drainage area 
of the tumor are excised. 
Previous reports have shown an incidence of malignancy as 
defined by regional lymph node involvement,  ranging from 30% 
to 60%. In our group of patients, 100% were malignant, includ- 
ing one patient whose primary tumor was only 0.15 mm in 
diameter. As a result, we consider ail duodenal tumors to be 
associated with lymph node involvement unless proved other- 
wise. 
Although our approach to these malignant duodenal  gastri- 
nomas has been conservative in terms of avoiding pancreati- 
coduodenectomy, the results thus far have been gratifying. 
Only long-term follow-up will determine whether patients cur- 
rently biochemically "cu red"  will remain so, although we have 
already accumulated a small group who have maintained nor- 
mal gastrin levels for more than 5 years. Fur thermore,  Ober- 
helman's  long-term results after excisional therapy of duodenal 
gastrinomas, rive of which were malignant, showed that an 
excellent initial result was sustained for 2 to 11 years [2]. In his 
series, 7 patients were treated with local excision, and 3 had 
pancreaticoduodenectomies with one postoperat ive death. His 
patients were ail treated during the era before effective drug 
therapy was available to control gastric hyperacidity.  We have 
intentionally avoided pancreat icoduodenectomy and its poten- 
tial morbidity because omeprazole can effectively control gas- 
tric acid should conservative surgical excisions fail. 
Our approach to the MEN-I  patients with ZES is based on the 
fact that the source of gastrin in these patients is from discrete 
tumors rather than from islet cell hyperplasia and nesidioblas- 
tosis, which are consistent findings in the MEN-I  pancreas [13]. 
Many of these patients have additional neuroendocrine tumors 
in the body or tail of the pancreas that may secrete other 
hormones or be malignant. We previously selected operative 
candidates based on TSVS but currently consider that ail 
MEN-I  patients should be explored unless liver metastases 
have been demonstrated by CT scan or angiography. Our 
experience suggests that most but not all MEN-I  patients have 
gastrinomas within the gastrinoma triangle [11]. These lesions 
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are most likely to be in the duodenum but may be present in 
both duodenum and pancreatic head [7]. Because duodenal 
tumors in MEN-I patients are often smaU and multiple, a 
duodenotomy and complete exploration from the pylorus to the 
ligament of Treitz is necessary in ail patients. Ail peripancreatic 
and periduodenal lymph nodes should be excised because the 
incidence of microscopic metastases is at least 60% and may be 
even higher. In this current group of patients, ail three had 
grossly apparent lymph node metastases. Any tumors palpable 
in the head or uncinate process of the pancreas should be 
enucleated. Although intraoperative ultrasonography may be 
useful in this regard, most gastrin-secreting neuroendocrine 
tumors arising in the pancreas are 1 cm or larger in diameter and 
are readily palpable [11, 14]. Our emphasis on performing a 
distal pancreatectomy is based on the fact that in each of our 
previous cases and in those in the present series ail had at least 
one or more discrete neuroendocrine tumors in the body or tail. 
Although the results in the MEN-I ZES patients are unlikely to 
be uniformly successful, it is our belief that many of these 
patients can be rendered eugastrinemic, providing their proce- 
dures are completed as described. Furthermore, the chances of 
developing other neuroendocrine syndromes or hepatic metas- 
tases should be significantly reduced. 
R›233 
Des › r› ont d›233 que les gastrinomes primitifs 
› localis› au duod› dans 30 ” 40% des cas, beaucoup 
plus fr› que commun› admis. La d› 
de ces tumeurs reste souvent difficile par des investigations 
conventionelles et n› une duod› avec une 
exploration et une palpation m› de la muqueuse 
duod› ›233 D'aussi petites tumeurs que de 1 ou de 2 
mm peuvent œ accompagn› de m› ganglionnaires. 
Sept cas de gastrinomes duod› trait› en deux ans, sont 
›233 Quatre avaient un syndrome de Zollinger-Ellison (SZE) 
et trois avaient un syndrome MEN-I. Tous ces patients avaient 
un gastrinome malin car tous avaient des m› ganglion- 
naires et dans un cas, des m› h› En cas de 
SZE sporadique, une eugastrin› a ›233 obtenue par excision 
de la tumeur, associ› ” une lymphad› et, dans un cas, 
” une lobectomie h› Deux des trois patients ayant un 
syndrome MEN-I sont devenus eugastrin› aprš des 
interventions similaires associ› dans un cas ” une pancr› 
tectomie distale. La duod› est un geste essentiel dans le 
cas d 'un  SZE sporadique lorsqu'on ne retrouve pas de tumeur, 
et chez tous les patients ayant un syndrome MEN, quelle que 
soient les donn› pancr› La lymphad› r› 
nale est › importante en cas de tumeur duod› 
Resumen 
Estudios recientes han demostrado que el duodeno es un lugar 
m~is comtin (30--40%) de ubicaci6n de gastrinomas primarios de 
lo que habfa sido previamente reportado. 
Estos tumores frecuentemente est~in ocultos en la explo- 
raci6n convencional y requieren duodenotomia y meticulosa 
evaluaci6n de la mucosa por eversi6n y palpaci6n directa para 
su detecci6n. Adem~is, tumores pequefios, de 1 y 2 mm, pueden 
estar asociados con met~istasis ganglionares. Se informan 7 
casos adicionales de gastrinomas duodenales tratados en un 
periodo de dos afios. Cuatro tenfan sfndrome de Zollinger- 
Ellison espor~idico (SZE) y tres sfndrome de NEM-1. Todos los 
7 pacientes tenian gastrinomas duodenales malignos compro- 
bado por la presencia de ganglios linfgtticos metast~isicos y, en 
un caso, tambi› una met~istasis hep~itica grande. La resecci6n 
local del tumor, la disecci6n de los ganglios y, en un caso, la 
lobectomia hep~itica, resultaron en eugastrinemia en los cuatro 
pacientes con SZE. Dos de los tres con SNEM-1 tambi› 
aparecieron eugastrin› luego de procedimientos similares 
y la adici6n de pancreatectomfa distal. 
La duodenotomia es considerada un procedimiento esencial 
en pacientes con SZE espor~idico cuando no se encuentra tumor 
pancre~itico, en todos los pacientes con SNEM-1 SZE, no 
importa cuales sean los hallazgos en el p~increas. La resecci6n 
de los ganglios regionales tambi› es esencial en presencia de 
tumor duodenal. 
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